AMRN earnings call for the period ending December 31, 2023.
The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.
AMRN earnings call for the period ending September 30, 2023.
The drugmaker announced a major corporate reorganization and a new CEO.
AMRN earnings call for the period ending March 31, 2023.
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.